Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (REXN)

REXN RSS Feed
Add REXN Price Alert      Hide Sticky   Hide Intro
Moderator: Crozz
Search This Board: 
Last Post: 6/19/2019 2:51:06 PM - Followers: 218 - Board type: Free - Posts Today: 0



   
 



   http://www.rexahn.com/cms/    

    http://finance.yahoo.com/q/ks?s=RNN

       

About

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

RX-3117 is a novel, oral, small molecule nucleoside compound.  Once intracellularly activated (phosphorylated) by the enzyme UCK2, it is incorporated into the DNA or RNA of cells and inhibits both DNA and RNA synthesis, which induces apoptotic cell death of tumor cells.  Because UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues, RX-3117 offers the potential for a targeted anti-cancer therapy with an improved efficacy and safety profile, and we believe it has therapeutic potential in a broad range of cancers, including pancreatic, bladder, colon, and lung cancer.  RX-3117 has received “orphan drug designation” from the U.S. Food and Drug Administration (“FDA”) and from the European Commission (“EC”) for pancreatic cancer.

RX-5902 (Supinoxin™) is a potential first-in-class small molecule inhibitor of phosphorylated-p68, a protein that we believe plays a key role in cancer cell growth, progression and metastasis through its interaction with beta-catenin.  Phosphorylated p68, which is highly expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation of cancer cells and tumor growth.  RX-5902 selectively blocks the interaction of phosphorylated p68 with beta-catenin, thereby decreasing the proliferation or growth of cancer cells in preclinical models.  In addition, multiple pre-clinical models suggest that RX-5902 enhances the efficacy of immunotherapy. We have evaluated RX-5902 in a Phase 1 dose escalation study in patients with a diverse range of metastatic, treatment-refractory tumors, including breast, ovarian, colorectal, and neuro-endocrine tumors.  In February 2017, we initiated a Phase 2a clinical study of RX-5902 in patients with metastatic triple negative breast cancer (“TNBC”).

RX-0201 (Archexin®) is a potential best-in-class, potent inhibitor of the protein kinase Akt-1, which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.  RX-0201 is the subject of a research and development collaboration with Zhejiang Haichang Biotechnology Co., Ltd. (“Haichang”) for the development of RX-0201 for hepatocellular carcinoma. RX-0201 has received orphan drug designation from the FDA for renal cell carcinoma (“RCC”), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.

 

 Rexahn  Pipeline

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com   


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

REXN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN News: Certification by the Exchange Approving Securities for Listing (cert) 06/10/2019 09:32:00 AM
RNN News: Securities Registration (section 12(b)) (8-a12b) 06/07/2019 04:56:42 PM
RNN News: Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeeme... 06/07/2019 04:41:51 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 06/07/2019 04:22:54 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 06/07/2019 04:22:41 PM
PostSubject
#3884   This company’s pipeline has so much potential. I’ve Crozz 06/19/19 02:51:06 PM
#3883   Please update the ticker on this board to Crozz 06/19/19 02:42:07 PM
#3882   Rexahn Announces Move to Nasdaq Crozz 06/19/19 02:37:57 PM
#3881   Why move to NASDAQ right now? This is Crozz 06/19/19 02:30:43 PM
#3880   News: $RNN Biotech Brief: Optimism Rising For Cancer whytestocks 04/17/19 08:31:07 AM
#3879   Right?!? Love that last kick to the crotch DorianGray 04/16/19 11:25:04 PM
#3878   * * $RNN Video Chart 04-16-2019 * * ClayTrader 04/16/19 04:53:33 PM
#3877   Massive news on low floater, in with starter UP Trend 04/16/19 10:06:53 AM
#3876   News: $RNN Rexahn and BioSense Global Announce Collaboration whytestocks 04/16/19 10:00:48 AM
#3875   could have made some money but instead decided Mistr Tommy 04/16/19 09:59:35 AM
#3874   Can we get to 174 so I can ttubular 04/16/19 09:53:03 AM
#3873   It should def run with the big deal airahim 04/16/19 09:09:20 AM
#3872   I didnt realize there is only 4 million Mistr Tommy 04/16/19 09:06:20 AM
#3871   Exactly. Could be a crazy run today QuidRunner 04/16/19 08:57:21 AM
#3870   Yup! We now have a super low floater. crudeoil24 04/16/19 08:56:29 AM
#3869   Wow, nice... would like to see some circuit QuidRunner 04/16/19 08:54:04 AM
#3868   ROCKVILLE, Md. and SUZHOU, China, April 16, 2019 crudeoil24 04/16/19 08:28:36 AM
#3867   1 more reverse and I may owe them kpisme 04/11/19 04:12:37 PM
#3866   I now need the price to go to ttubular 04/11/19 12:29:58 PM
#3865   Agreed. What a toilet wipe. kpisme 04/11/19 11:57:10 AM
#3864   Reverse stock split 1 for 12 This sucks big time ttubular 04/10/19 04:24:40 PM
#3863   I personally decided to get out on this PennyWorld 02/19/19 06:05:02 PM
#3862   I understand 100% what your saying. I'm not Crozz 02/19/19 03:04:39 PM
#3861   I no longer buy penny stocks under $1 PennyWorld 02/15/19 02:46:20 PM
#3860   I rode out the split in May and HSTN 02/15/19 02:42:52 PM
#3859   What I was really trying to say is.... PennyWorld 02/11/19 03:26:34 PM
#3858   I agree with everything you said. What I Crozz 02/11/19 12:00:47 PM
#3857   disagree.. R/S is not factored into the price. PennyWorld 02/08/19 05:48:15 PM
#3856   Insiders are executing options, so that they can Crozz 02/08/19 12:11:07 PM
#3855   If you own shares, Vote against the R/S Crozz 02/08/19 11:49:25 AM
#3854   DELIST PLEASE this is and will always be kpisme 02/07/19 05:46:11 PM
#3853   It really doesn't make any difference whether or Crozz 02/07/19 03:39:38 PM
#3852   Longs don't seem to ever get rewarded here. Crozz 02/07/19 03:35:56 PM
#3851   I wouldn't get too excited, that was a Crozz 02/07/19 03:31:19 PM
#3850   WTF...finally some good news! A patent notification...And they Crozz 02/07/19 03:28:32 PM
#3849   Hold tight....Insiders didn't just buy for no reason. 420man 02/04/19 08:38:25 AM
#3848   Great science...I wish management would sell this to Crozz 01/30/19 08:44:40 AM
#3847   * * $RNN Video Chart 01-23-2019 * * ClayTrader 01/23/19 05:50:48 PM
#3846   Split on May 5th 2017 maggie61 01/23/19 03:49:32 PM
#3845   Thanks. Clearly the trick is to flip by PennyWorld 01/23/19 10:34:42 AM
#3844   https://www.splithistory.com/rnn/ cintrix 01/23/19 10:25:30 AM
#3843   Does anyone know when the last time RNN PennyWorld 01/23/19 10:21:12 AM
#3842   Wow with the reaction to this offering the ttubular 01/23/19 09:15:11 AM
#3841   Where’s the news from the conference ttubular 01/21/19 09:08:39 PM
#3840   don't hold your breath - how many times DorianGray 01/18/19 10:32:44 AM
#3839   Looks like the results r good moving on up ttubular 01/17/19 03:23:30 PM
#3838   * * $RNN Video Chart 01-14-2019 * * ClayTrader 01/14/19 05:42:38 PM
#3837   Rexahn Announces Presentation of RX-3117 Data at the pennytrader33 01/14/19 03:28:59 PM
#3836   Leadership Change...yeah who cares! Hopefully this new CEO Crozz 11/16/18 11:21:12 AM
#3835   Is it over for Rnn new lows everyday What ttubular 10/23/18 02:47:03 PM
PostSubject